Analysts Set Keros Therapeutics Price Target at $21.86 Amid Mixed Ratings

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have garnered a consensus recommendation of “Hold” from ten research firms currently tracking the company, according to MarketBeat.com. Analysts provide a mixed outlook, with one rating the stock as a sell, four suggesting a hold, and five advocating a buy. The average 12-month target price set by these brokerages stands at $21.86.

Recent assessments have revealed varying perspectives on Keros Therapeutics. For instance, Wall Street Zen downgraded its rating from “Hold” to “Sell” on March 7, 2023. Additionally, Weiss Ratings reiterated a “Sell (D+)” rating in a report from December 29, 2022. Meanwhile, Bank of America raised its price objective from $18.00 to $19.00, maintaining a “Neutral” rating in a note released on November 28, 2022. Zacks Research also downgraded Keros from a “Strong Buy” to a “Hold” rating on January 1, 2023. On March 5, 2023, Wells Fargo & Company adjusted its target price from $23.00 to $20.00, while setting an “Overweight” rating for the company.

Keros Therapeutics Earnings Report Highlights Challenges

Keros Therapeutics recently released its quarterly earnings data on March 4, 2023. The company reported earnings per share of ($0.86), falling short of the consensus estimate of ($0.49) by ($0.37). Revenue for the quarter amounted to $0.39 million, significantly below analysts’ expectations of $3.66 million. This marked an 87.2% decline in revenue year-over-year, as the company had reported earnings of ($1.14) per share during the same period in the previous year. Analysts predict that Keros Therapeutics will post an average earnings per share of ($4.74) for the current year.

Institutional Investors Show Interest in Keros

Recent activity among institutional investors indicates a growing interest in Keros Therapeutics. Financial Management Professionals Inc. acquired a new stake in the company in the fourth quarter, valued at approximately $29,000. Similarly, Caitong International Asset Management Co. Ltd increased its holdings by 254.6% during the same period, now owning 1,624 shares valued at $33,000. Tower Research Capital LLC also raised its stake by 149.2%, owning 3,153 shares worth $42,000 after acquiring an additional 1,888 shares last quarter.

Other notable investments include Farther Finance Advisors LLC, which purchased a stake valued at $47,000, and SG Americas Securities LLC, which invested $103,000 in the third quarter. Currently, institutional investors and hedge funds collectively own approximately 71.56% of Keros Therapeutics’ stock.

Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for disorders related to erythropoiesis and iron regulation. The firm’s research is primarily centered on modulating the transforming growth factor-beta (TGF-β) superfamily to enhance red blood cell production, aiming to address significant unmet needs in conditions such as myelodysplastic syndromes and beta-thalassemia. Its lead product candidate, KER-050, is designed to improve effective erythropoiesis and reduce transfusion dependence in patients suffering from anemia related to these conditions.

As Keros Therapeutics navigates its challenges, market analysts will be closely monitoring the company’s performance, particularly in light of its recent earnings report and ongoing institutional investment trends.